Cholesterol Clinical Trials 2024

What are the top hospitals conducting cholesterol research?

When it comes to cutting-edge clinical trials focused on cholesterol management, Novartis Investigative Sites are leading the way in various locations across the United States. In Boca Raton, researchers are currently conducting three active cholesterol trials, marking their dedication to finding innovative solutions for this prevalent condition. Interestingly, their first recorded cholesterol trial dates back to 2021, demonstrating their commitment to staying ahead of emerging health concerns.

Moving northwards to Birmingham and Richmond, Novartis Investigative Sites continue their vital work in advancing our understanding of cholesterol with two ongoing trials at each location. Impressively, even with a shorter history in this field compared to other sites, these hospitals have already conducted a notable number of all-time cholesterol studies.

Meanwhile Shreveport and Atlanta also play significant roles within the research landscape surrounding cholesterol management. Both sites have two active cholesterol trials underway as they contribute towards unraveling new insights into this pervasive health challenge. It is worth highlighting that these institutions initiated their respective involvement in studying high levels of blood lipids only recently; recording their first-ever tests focusing on tackling such issues from 2023 onwards

These diverse Novartis Investigative Sites demonstrate impressive progress and collaboration when it comes to battling high cholesterol levels that impact millions worldwide. Through ongoing efforts and groundbreaking discoveries generated by these clinical trials across different locations throughout America; scientists hope not only to find more effective treatments but also improve overall cardiovascular health outcomes for individuals struggling with lipid disorders

Which are the best cities for cholesterol clinical trials?

Cincinnati, Ohio; Boca Raton, Florida; and New york, New York are among the best cities for cholesterol clinical trials. Cincinnati leads with 12 active trials focused on treatments like Active, lerodalcibep, and Inclisiran. Boca Raton follows closely behind with 7 ongoing studies examining interventions such as Inclisiran, MK-0616, and Obicetrapib. Similarly, New York City also has 7 active trials investigating various cholesterol-lowering treatments including 4-Week LDL-Cholesterol (LDL-C)-Reduction Treatment, Inclisiran, and Obicetrapib. These three cities offer individuals opportunities to participate in cutting-edge research aimed at advancing our understanding of cholesterol management and promoting better health outcomes.

Which are the top treatments for cholesterol being explored in clinical trials?

Clinical trials are paving the way for new advancements in cholesterol treatment. Inclisiran, a promising drug with four ongoing clinical trials, is leading the pack. Since its introduction in 2017, it has garnered attention with a total of 12 cholesterol-related trials. Another contender making waves is MK-0616, currently being explored in two active trials and five all-time cholesterol studies since its listing in 2022. Equally noteworthy is obicetrapib, entering the scene in 2021 and already gaining traction with two ongoing trials and five all-time cholesterol studies under its belt. These treatments hold great potential to improve outcomes for individuals battling high cholesterol levels.

What are the most recent clinical trials for cholesterol?

Exciting developments are underway in the field of cholesterol management, with recent clinical trials offering potential breakthroughs. One such trial involves 2-Hydroxybenzylamine (2-HOBA), a promising compound being studied in Phase 2 for its effectiveness in managing cholesterol levels. Additionally, MK-0616 has shown promise as a potential treatment option for high cholesterol, with Phase 3 trials demonstrating positive outcomes. Another Phase 3 study investigated the efficacy of Inclisiran and Inclisiran Sodium 300mg on lowering cholesterol levels. These advancements highlight the ongoing efforts to find innovative solutions for individuals battling elevated cholesterol and pave the way towards improved treatments in the future.

What cholesterol clinical trials were recently completed?

Recent advancements in cholesterol research have been supported by a multitude of completed clinical trials. Notably, Merck Sharp & Dohme Corp.'s trial exploring the potential of MK-0616 concluded in March 2022. In April 2021, LIB Therapeutics LLC wrapped up their promising study on lerodalcibep. Earlier milestones include Regeneron Pharmaceuticals' completion of an evinacumab trial in June 2020 and LIB Therapeutics LLC's previous successful investigation into lerodalcibep, finalized in December 2019. Additional significant contributions were made with the completion of Novartis' Inclisiran Sodium trial in April 2019 and Sanofi's Ezetimibe trial concluding in May 2018. The wealth of data from these diverse studies drives forward our understanding and treatment options for managing cholesterol-related conditions.